<DOC>
	<DOCNO>NCT00003288</DOCNO>
	<brief_summary>Phase I trial study effectiveness tirapazamine plus cyclophosphamide treat child refractory solid tumor . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell .</brief_summary>
	<brief_title>Tirapazamine Plus Cyclophosphamide Treating Children With Refractory Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose dose limit toxicity tirapazamine administer cyclophosphamide intravenous infusion child refractory solid tumor . II . Determine incidence severity toxicity tirapazamine cyclophosphamide patient . III . Determine safe tolerable dose tirapazamine administer cyclophosphamide phase II study indication . IV . Determine pharmacokinetics tirapazamine child adolescent receive combination tirapazamine cyclophosphamide . V. Determine preliminary evidence antitumor activity tirapazamine cyclophosphamide . OUTLINE : This dose escalation study . Patients receive tirapazamine 2 hour intravenous infusion ( hour 0-2 ) follow 2 hour later 30 minute intravenous infusion cyclophosphamide . This course repeat every 3 week patient partial/complete response stable disease maximum 1 year . Cohorts 3-6 patient treat dose level tirapazamine . Dose escalation tirapazamine occur 0 3 patient 1 6 patient experience dose limiting toxicity ( DLT ) . If DLT experience 1 3 patient give dose level , 3 additional patient treat dose level . If none 3 additional patient dose level experience DLT , dose escalate . If DLT experience 1 additional 3 patient , maximum tolerate dose ( MTD ) exceed 3 patient treat next low dose level ( defined MTD ) . A total six patient treat MTD . If DLT prove neutropenia , patient must also meet additional eligibility criterion list stratum 2 . If neutropenia continue DLT stratum 2 , additional patient receive subcutaneous filgrastim ( granulocyte colony-stimulating factor ; G-CSF ) begin 24 hour cyclophosphamide . A second MTD may determine chemotherapy G-CSF . Patients follow every 6 month 4 year , annually thereafter .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tirapazamine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor refractory conventional therapy effective therapy know Brain tumor eligible Brainstem glioma may waive histological verification requirement Neurologic deficit associate CNS malignancy must stable minimum 4 week prior study No leukemia Stratum 2 No marrow involvement PATIENT CHARACTERISTICS : Age : 21 Performance status : Karnofsky Lansky 50100 % Life expectancy : At least 8 week Absolute neutrophil count least 1,000/mm3 Platelet count least 75,000/mm3 Hemoglobin least 9 g/dL Bilirubin le 1.5 mg/dL SGPT le 5 time normal Creatinine normal age OR creatinine clearance least 70 mL/min Shortening fraction least 27 % normal OR ejection fraction great 50 % normal Not pregnant nursing Negative pregnancy test require PRIOR CONCURRENT THERAPY : No concurrent anticancer therapy At least 6 month since bone marrow transplant evidence graft versus host disease At least 1 week since growth factor No concurrent granulocyte colonystimulating factor Recovered prior immunotherapy Stratum 2 : No prior bone marrow transplantation ( without total body irradiation ) At least 6 week since prior nitrosourea At least 2 week since prior myelosuppressive chemotherapy Dexamethasone must stable decrease dose 2 week prior study Recovered prior chemotherapy Stratum 2 : No 2 prior chemotherapy regimen At least 2 week since local palliative radiotherapy ( small port ) At least 6 month since prior substantial bone marrow radiation ( e.g. , cross sectional radiotherapy [ great 24 Gy ] , total body irradiation , hemi pelvic radiotherapy ) Recovered prior radiotherapy Stratum 2 : No prior central axis radiation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
</DOC>